Status:
ACTIVE_NOT_RECRUITING
Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment
Lead Sponsor:
CHU de Quebec-Universite Laval
Collaborating Sponsors:
Ferring Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
18-95 years
Phase:
NA
Brief Summary
The purpose of this study is to compare toxicities between 2 external beam radiation fractionation schemes plus a brachytherapy boost for prostate cancer. Our current standard use a 2 Gy per fraction ...
Detailed Description
30 patients with intermediate / extensive low risk (all core biopsies involvements \> 50%) prostate cancer (not necessitating to treat the nodal regions) will be included in this study. Patient stage ...
Eligibility Criteria
Inclusion
- 30 patients
- intermediate / extensive low risk (all core biopsies involvements \> 50%)
- prostate cancer (not necessitating to treat the nodal regions)
- Patient stage T1 - T2,
- Gleason score ≤ 7,
- PSA ≤ 20 will be considered
Exclusion
- patient unfit for biopsy or brachytherapy
- high or low risk prostate cancer
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01851018
Start Date
May 1 2012
End Date
June 1 2025
Last Update
March 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHUdeQuebec
Québec, Canada, G1R 2J6